Swayamjeet Satapathy

2 weeks ago | jnm.snmjournals.org | Swayamjeet Satapathy |Chandan K. Das |Shikha Goyal |Ashwani Sood

177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial Swayamjeet Satapathy, Chandan K. Das, Shikha Goyal, Ashwani Sood, Kannan Periasamy, Piyush Aggarwal, Komal Preet, Shrawan K. Singh, Ravimohan S. Mavuduru, Girdhar S. Bora, Aditya P. Sharma, Gaurav Prakash, Rajender Kumar, Harmandeep Singh, Bhagwant R.

Jan 7, 2025 | jnm.snmjournals.org | Swayamjeet Satapathy |Piyush Aggarwal |Ashwani Sood |Kunal R. Chandekar

177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.